INCLINE VILLAGE, Nev. , March 7, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018 , on Thursday, March 14, 2019 , after market

INCLINE VILLAGE, Nev. , March 5, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, and Peter Garcia , PDL's chief financial officer, will present at the Cowen 39 th Annual Health Care

INCLINE VILLAGE, Nev. , March 4, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL", NASDAQ: PDLI) announces the U.S. commercial launch of an authorized generic of Tekturna ® , aliskiren hemifumarate 150 mg and 300 mg tablets.  The authorized generic has the same drug formulation as Tekturna.

INCLINE VILLAGE, Nev. , Nov. 19, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare Conference in New York City.  The session will be webcast live and will occur on Tuesday, November 27, 2018 , at

Announces CEO succession plan INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including: Third Quarter Financial Highlights Total revenues of $67.9

INCLINE VILLAGE, Nev. , Oct. 31, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018 , on Tuesday, November 6, 2018 , after market close.  PDL's management

INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position.  Mr. Imbrogno brings to PDL more than 30 years of public accounting and financial reporting experience and will

INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York City. The session will be webcast

INCLINE VILLAGE, Nev. , Sept. 24, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock.  Purchases may be made in open-market transactions, in block

INCLINE VILLAGE, Nev. , Aug. 30, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will present at the H.C. Wainwright 20 th Annual Global Investment Conference next week in New York City.  The session

INCLINE VILLAGE, Nev. , Aug. 8, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) reports financial results for the three and six months ended June 30, 2018 including: Second Quarter Financial Highlights Total revenues of $46.6 million .

INCLINE VILLAGE, Nev. , Aug. 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the "Royalty Agreement") with Depomed, Inc. (" Depomed ") under which PDL acquired all of Depomed's remaining rights to royalties and

INCLINE VILLAGE, Nev. , Aug. 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2018 , on Wednesday, August 8, 2018 , after market close.  PDL's

INCLINE VILLAGE, Nev. , June 22, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth G. O'Farrell has been named to the Company's Board of Directors, effective June 22, 2018 and increasing the

INCLINE VILLAGE, Nev. , June 11, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced that at its 2018 annual meeting of stockholders held June 8, 2018 , the Company's stockholders elected Shlomo Yanai to the Company's Board of Directors.  The Company